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cense.Abstract Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchy-
mal tumors of the gastrointestinal tract (GIT) and are believed to originate from the interstitial cell
of Cajal. Management of GIST has evolved very rapidly in the last decade.
Aim: To report our surgical experience in the treatment of GIST patients, to evaluate the prognos-
tic factors and to discuss some controversial issues about the role of target therapy.
Patients and methods: One hundred and twenty seven consecutive patients who underwent surgical
resection for GISTs at Nasser Institute (98 patients) and NCI, Cairo University (29 patients) from
January 2000 to December 2009 were reviewed retrospectively. The clinical and pathological fea-
tures of patients were collected. Also data about treatment variables, patterns of failure and factors
that predict survival were collected and analyzed.
Results: Of the 127 patients, 81 (64%) had primary disease without metastasis, 11 (9%) had met-
astatic lesions at presentation, and 35 (27%) presented with recurrence (isolated, metastasis or
both). Patients with primary disease underwent complete resection of gross disease. The 5-year
overall survival was 53.4% and disease free survival (DFS) was 46.5%. The median DFS was






32 M. Al-Kalaawy et al.presentation, gastric origin and tumor size. Failures after resection were predominantly intra-
abdominal (original site, peritoneal, and liver), and rarely lungs.
Conclusion: Surgical resection is the mainstay of treatment of GIST. Tumor size and gastric origin
were the predicators for DFS in patients presenting with primary disease.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Gastrointestinal stromal tumor (GIST) is the most common
gastrointestinal (GI) mesenchymal tumor, which accounts for
0.2% of all GI tumors [1]. Gastrointestinal stromal tumors
(GISTs) have been recognized as a biologically distinctive tu-
mor type, different from smooth muscle and neural tumors of
the gastrointestinal tract. It is now believed that GISTs origi-
nate from gastrointestinal pacemaker cells known as interstitial
cells of Cajal that control gut, or from a precursor of these cells
[2]. The identiﬁcation of mutations mostly in exon 11 and to a
lesser extent in exons 9 and 13 of the c-kit proto-oncogene cod-
ing for c-kit (CD117) in many GISTs, has resulted in a better
understanding of their oncogenic mechanism [3].
The term was ﬁrst coined byMazur and Clark in 1983 to de-
scribe a heterogeneous group of gastrointestinal non-epithelial
neoplasms [4]. In 1998, Hirota and co-workers reported that
GISTs contained activating c-kit mutations, which play a cen-
tral role in its pathogenesis [5]. Furthermore, GISTs express
CD34 and the KIT on their surface [6]. Finally, GISTs are de-
ﬁned as pleomorphic mesenchymal tumors of the GI tract that
express the KIT protein CD117 and often also CD34 on immu-
nohistochemistry [7]. Over 90% of GISTs occur in adults over
40 years of age, with a median age of 63 years. However, GIST
cases have been reported in all ages, including children. The inci-
dence does not differ with sex, though a study reported that
there is a slight predominance of males [8].
The prediction of malignant potential of GISTs based on
clinico-pathological features is often difﬁcult. Large mitotically
active tumors with necrosis predictably behave aggressively [9].
The two main methods of spread of malignant GISTs are liver
metastases and intra-abdominal spread [10]. It is now accepted
that categorizing GISTs into low, intermediate and high-risk
tumors based on an estimation of their potential for recurrence
and metastases is more appropriate than dividing them into
benign and malignant categories [11].
This study reports our experience in the surgical treatment
of GIST patients with evaluation of the prognostic factors.
Patients and methods
From January 2000 to December 2009, 127 patients with GIST
(different nationalities, mainly Palestinians, 57%) were oper-
ated upon at the department of surgery, National Cancer Insti-
tute, Cairo University and Nasser Institute, Cairo, Egypt. All
patients had full laboratory workup, chest radiogram and
computed tomography (CT) of the abdomen and the pelvis
for surgical planning. Upper or lower GIT endoscopies were
performed when indicated with biopsy (if feasible). Our policy
discourages CT or ultrasound guided biopsy as it may cause
tumor rupture, hemorrhage and peritoneal seedling with nega-
tive impact on ﬁnal outcome.The treatment philosophy with regard to GIST emphasizes
complete gross removal of the tumor (R0). Resections are clas-
siﬁed as incomplete (R2) when the tumor is unresectable at
exploration or when gross residual disease is present after
resection and complete (R1) when all gross diseases are excised
regardless of microscopic margins. Resection of metastases is
performed in selected patients in whom the primary tumor is
controlled. Systemic chemotherapy and radiation therapy were
excluded from the analyses in this report because they were
used sporadically.
An experienced pathologist reviewed all tumors for histolog-
ical conﬁrmation of diagnosis and evaluation of morphological
and immune-histochemical characteristics including expression
of CD117 and CD34. Patient and tumor characteristics were
evaluated as well as treatment variables with special emphasis
to study patterns of failure and prognostic factors that predict
survival. Risk factors including tumor size, mitotic count/50
high power ﬁeld (HPF) and resection margin were assessed.
Statistical methods
Data were analyzed using SPSS win statistical package version
15. Quantitative data were presented as median and range.
Qualitative data were expressed as frequency and percentage.
Survival was calculated by the Kaplan–Meier method. Overall
survival (OS) was calculated from the date of pathological
diagnosis to date of death or last follow up. Disease free sur-
vival (DFS) was calculated from date of surgical intervention
to date of recurrence or death or last follow up. The relations
of patient, tumor and treatment characteristics to outcome
(DFS, OS and recurrence) were tested by univariate analysis
using the Log rank test. Cox regression is used for multivariate
analysis of signiﬁcant factors affecting survival in univariate
analysis. A p< 0.05 was considered signiﬁcant.
Results
Patient characteristics
Patients were 81 males (63.8%) and 46 females (36.2%), with
median age of 54 years (range, 18–77 years). Table 1 shows
that 81 patients (63.8%) presented with primary tumors, 11
patients (8.7%) had metastatic lesions in addition, whereas
and 35 patients (27.6%) presented with recurrent disease either
isolated recurrence, metastasis or both.
Tumor characteristics
Tumor sites are shown in Table 2. The most common site of
tumor was gastric in 41.7% of cases followed by small
intestinal in 31.5%. The median tumor size was 18 cm (rang:
5–42 cm). The histopathological and immunologic tumor
Table 1 Mode of presentation of the studied group (n= 127).
Presentation Number Percentage (%)
Primary disease 81 63.8
Primary disease with metastases 11 8.6
Hepatic 10 7.8





Table 2 Tumor site in 127 cases of GIST.
Anatomic site Number Percentage (%)
Stomach 53 41.7





Female genital 1 0.8
Table 3 Histopathological and immuno-pathological features
of tumors in 127 cases of GIST.
Number Percentage (%)
Histopathology
Spindle cell 84 66.1
Epithelioid 23 18.1
Mixed 20 15.8







Table 4 Surgical treatment in 127 patients with GIST.
Operation Number
Partial gastrectomy 49
Gastrectomy + splenectomy 2
Gastrectomy + colectomy + splenectomy 1
Gastrectomy + distal pancreatectomy + splenectomy 1
Resection of small intestinal loops 40
Colectomy 12
Transverse colectomy + small intestinal loops 1
Low anterior resection 3
Abdomeno-perineal resection 1
Esophagogastric resection (Ivor-Lewis operation) 5
Shell-out esophageal 1
Omentectomy 2
Excision of retroperitoneal tumors 3
Hepatic resection 13
Hepatic resection + resection of recurrent masses 3
Panhysterectomy + hepatic metastatectomy 1
Total no. of operations 138a
a More than 1 procedure may be done for a patient.
Figure 1 A 40-year old man with recurrent GIST: (a) huge tumor in
postoperative specimen after splenectomy, distal gastrectomy and tran
Gastrointestinal stromal tumors (GISTs), 10-year experience: Patterns 33characteristics are shown in Table 3. Spindle cell tumors were
the main histopathological type.
Surgical treatment
All patients underwent surgical exploration. Complete resec-
tion was accomplished in 94 patients (74%); 81 patients
(63.7%) with primary disease, three patients (27.3%) with
metastatic disease and 10 patients (28.6%) with recurrent dis-
ease. The details of the extent of surgical resection are shown
in Table 4 and Figs. 1–9.
Postoperative complications
There were no postoperative mortalities. Postoperative mor-
bidity was reported in nine patients (7.1%). Reoperation was
resorted to in two patients (1.6%). The ﬁrst patient had a
subphrenic abscess that was surgically drained after failure
of ultrasound guided aspiration. The second patient had been
explored to relieve postoperative adhesive intestinal obstruc-
tion. Five patients had wound infection and two patients had
wound dehiscence, but all were managed conservatively.vading stomach, transverse colon, part of small intestine and (b)
sverse colectomy.
Figure 2 Postoperative specimen of recurrent GIST after resec-
tion of part of colon, diaphragm and proximal gastrectomy.
Figure 3 Postoperative specimen after resection of gastric GIST.
Figure 5 Postoperative specimen of mesenteric GIST showing
part of small intestine and part of omentum.
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We followed up the 94 patients who underwent complete resec-
tion for the detection of recurrences. There were 43 cases of
recurrence; 28 local recurrence, 9 distant metastases and 6 both
local recurrence and metastases. Sites of distant metastases
were liver (n= 8) and lung (n= 7). Patients who suffered met-Figure 4 Gastric GIST: (a) Preoperative CT scan, (b) partial gast
ulceration.astatic or recurrent disease during the follow-up period were
considered for surgical resection when all gross disease could
be resected. This redo surgery was performed in 37/43 patients.
Four mortalities (10.8%) have been encountered in this group
within the ﬁrst month after surgery.
Survival
Only those patients who had complete resection (n= 94) had
survival chance. Those with inoperable lesions survived few
weeks after presentation. For the 94 patients who underwent
curative surgery, the median follow-up period was 57 months
(range 14–108 months). At 5 years, the overall survival was
53.4% and disease free survival was 46.5%. The median
DFS was 43.0 months (95% CI: 21.2–64.9).
On univariate analysis of the clinicopathological risk fac-
tors (Table 5), tumor size, mitotic index, gastric origin
(Fig. 10) and primary presentation status (Fig. 11) predicted
survival. Age, sex and the microscopic margin did not inﬂu-
ence the outcome. On multivariate analysis using Cox regres-ric resection, (c) tumor covered by intact mucosa and a central
Figure 6 (a and b) Postoperative specimens of gastric GIST.
Figure 7 A 32-years old male with recurrent GIST: (a) preoperative CT scan, (b) intra operative view, (c) postoperative specimen of
showing part of small intestine transverse colon and part of stomach.
Figure 8 Recurrent small intestinal GIST with liver deposit: (a) intra-abdominal recurrence, (b) liver deposit, (c) specimen after wider
resection and metastatectomy.
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Figure 9 Mass at transverse colon and small intestine: (a) preoperative CT scan, (b) postoperative specimen showing part of small
intestine and transverse colon.
Table 5 Disease free survival of the patients with GIST who underwent complete resection in relation to the risk factors (n= 94).
Item No. Median DFS (months) Cumulative DFS (%) P value
Age (years)
<40 13 31.6 (0.0–71.8) 47.9 0.689
P40 81 43.0 (25.8–60.2) 46.2
Gender
Male 68 37.1 (7.6–66.6) 50.3 0.263
Female 26 a 56.9
Presentation
Primary 81 66.1 (31.5–100.8) 56.6 0.028
Recurrent or metastases 13 31.6 (15.6–47.5) 7.7
Site
Gastric 49 a 56.4 0.027
Others 45 20.3 (2.2–38.3) 38.5
Size (cm)
65 13 77.5 (59.1–95.8) 84.6 0.015
5–10 56 38.6 (20.9–56.3) 40.7
>10 25 6.6 (0.0–15.4) 38.7
Surgical margin
Negative microscopic margin 66 23.5 (0.5–58.2) 49.3 0.513
Positive microscopic margin 28 45.4 (22.8–67.9) 48.1
Mitosis per 50 HPF
65 11 77.5 (0.0–128.0) 81.8 0.046
5–10 58 38.6 (26.1–51.0) 44.4
>10 25 26.3 (8.8–43.7) 32.6
a No median value calculated.
36 M. Al-Kalaawy et al.sion, recurrence or metastasis at presentation (OR: 2.3, 95%
CI: 1.1–4.7), non-gastric origin (OR: 2.5, 95% CI: 1.3–4.8)
and tumor size >10 cm (OR: 6.2, 95% CI: 1.9–20.0) were
the independent variables predicting worse DFS (Table 6).
Discussion
We analyzed our results with 127 patients with GIST treated at
the department of surgery, National Cancer Institute, Cairo
University, and Nasser institute, Cairo, Egypt in the past
10 years. The present study reviewed the clinicopathological
features appraising the results of treatment, patterns of failure
and prognostic factors for survival.In our series, tumor originated most frequently from the
stomach (41.7%), the small intestine was the second most
frequent tumor origin. These ﬁndings are similar to other
reports [12]. All our patients were symptomatic at presentation.
This could be explained by the large size of tumors ranging
from 5 to 42 cmwith a median size of 18 cm. In contrast, aWes-
tern study reported that only 50–70% of patients are symptom-
atic [13]. Among 94 patients who underwent complete resection
(CR), those with tumor size 65 cm had a median DFS of
78 months compared to 38 months in those with tumor size
5–10 cm. The median disease free survival dropped signiﬁcantly
to 6.6 months when tumors were larger than 10 cm (p= 0.015).
Yao et al. [16] demonstrated that tumor size has a signiﬁcant
impact on overall survival.
Figure 10 DFS of patients with GIST who underwent complete resection in relation to tumor presentation (primary vs. recurrent/
metastatic tumors).
Figure 11 DFS of patients with GIST who underwent complete resection in relation to tumor site (gastric vs. others).
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cosal changes, as protrusion or indentation. Endoscopic ultra-
sonography (EUS) plays an important role in the diagnosticwork up of stromal tumors. As a rule, the EUS shows GIST
as a hypoechogenic mass originating usually from the muscu-
laris propria and muscularis mucosa. However contrast-en-
Table 6 Multvariate analysis of factors affecting disease free survival of the patients with GIST who underwent complete resection
(n= 94).
B SE p Value OR 95.0% CI for OR
Presentation 0.838 0.364 0.021 2.3 1.1–4.7
Mitosis (<5) 0.209
Mitosis (5–10) 0.421 0.656 0.521 1.5 0.4–5.5
Mitosis (>10) 0.894 0.664 0.178 2.4 0.7–9.0
Site 0.913 0.329 0.006 2.5 1.3–4.8
Tumor size (<5 cm) 0.006
Tumor size (5–10 cm) 1.058 0.558 0.058 2.9 1.0–8.6
Tumor size (>10 cm) 1.828 0.596 0.002 6.2 1.9–20.0
B: Regression coefﬁcient, SE: standard error, OR: Odds Ratio, CI: conﬁdence interval.
Mitosis ref. is <5; tumor size ref. is <5 cm.
38 M. Al-Kalaawy et al.hanced CT scan is currently the imaging modality of choice
with a solid exophytic pattern of growth that displays contrast
enhancement after its oral or intravenous administration,
together with the absence of associated lymphadenopathy
[14]. Although there is a role of endoscopic ultrasound guided
biopsy, we believe that preoperative percutaneous, open or
laparoscopic biopsy is discouraged as there is risk of hemor-
rhage, tumor rupture and peritoneal spillage. It is indicated
only for clearly unresectable lesions or when treatment might
be altered as in lymphoma or germ cell tumors [12,15].
Histological examination revealed spindle cell tumors in
66.1% of specimens, while 18% were epithelioid and 15.8%
were mixed. This is comparable with the described incidence
in other studies [17].
Surgical resection remains the treatment of choice for all
resectable tumors since it is the only chance for cure [1,12].
In this study, patients who underwent complete resection
had a 5 year survival of 53.4% which is comparable with other
reports [12,28,29].
A 1–2 cm margin was advocated to achieve adequate resec-
tion [18]. However more recently, Dematteo et al. [19] demon-
strated that tumor size (and not a wide negative microscopic
margin) was more important in determining survival. In our
study complete macroscopic resection was undertaken in 94/
127 patients (74%). The goal of surgery is complete resection
of gross disease avoiding tumor rupture and achieving negative
margins. However, because the status of the microscopic mar-
gins does not appear to be important for survival – as proved
in the current study – vital structures should not be sacriﬁced if
gross tumor clearance has already been attained [19]. The
shell-out procedure should be avoided except in difﬁcult loca-
tions (cervical esophagus, rectum), provided the patient is in-
formed for careful follow-up. Incomplete resection should be
performed only for palliation of emergency symptoms e.g.
bleeding, pain or mass effect [20]. Tumor rupture should be
avoided as it is associated with intra-abdominal dissemination
of tumor cells and subsequent high risk of local tumor recur-
rence [21]. We agree with De Matteo et al. and Blanke that
GISTs rarely go to lymph nodes, so lymphadenectomy in the
absence of gross involvement is not needed [12,22].
Treatment failures are known to affect almost half of GIST
patients treated by surgery alone [17] and tend to be found in
the liver in 65%, the peritoneal surface in 50% and in both in
about 20% [12]. In agreement with these ﬁndings, we foundtumor recurrence in 43 patients out of 94 patients who had
complete surgical resection, 8 patients had liver metastases
and 7 had pulmonary metastases while 23 patients had perito-
neal deposits. Liver metastases of GIST are usually multiple,
large in diameter, and localized in both lobes [23]. DFS of
the 94 patients was 46.5%.
Re-do surgery was performed in 37 of these 43 patients.
Aggressive surgical resection is justiﬁed in recurrent cases
[24]; thus, patients should be followed up regularly starting
from an early period after resection of the primary tumor, be-
cause early detection of metastasis could possibly enhance
complete cytoreduction of the recurrent tumor burden. Fur-
thermore, this complete cytoreduction followed by imatinib
therapy might be able to improve the survival of patients with
recurrent GISTs [20,25].
Different risk categories have been compiled by Fletcher
et al. [11], based on primary tumor diameter and mitotic
counts per 50 HPF which determine the risk of local recurrence
and survival. In our study primary tumor presentation, gastric
origin, tumor size and mitotic count had signiﬁcant inﬂuence
on DFS. This agrees with other studies [26,27].
Since the year 2000, there has been a shift in paradigm for
the treatment of GIST, and Kit/PDGFRA tyrosine kinase
inhibitors such as imatinib (Gleevec) have been applied in
the treatment of unresectable or recurrent GISTs. This oral
therapy has demonstrated good response in the majority of pa-
tients and has emerged as the gold standard treatment for pa-
tients with metastatic GISTs [20]. However, long-term success
is limited due to the development of imatinib resistance via sec-
ondary mutations or clonal selection [30]. In this study, 4 pa-
tients with metastatic disease and 13 patients with recurrent
disease received neoadjuvant Gleevec for 6 months.
Other inhibitors of Kit/PDGFRA receptors or downstream
signaling molecules targets, such as protein kinase theta and
tyrosine kinase inhibitors of VEGFRs, have been utilized in
cases where imatinib has failed [31]. As this drug is very expen-
sive it is not routinely used for outside clinical trials. Owing to
the costliness of imatinib, not all patients with GIST in this
study can afford imatinib adjuvant therapy. In addition, the
patients treated with imatinib for advanced GIST will inevita-
bly progress. Therefore, in the future we must evaluate the bio-
logical behavior of GIST accurately and carefully select the
patients with a high risk for tumor recurrence and metastasis
as candidates for imatinib adjuvant therapy in clinical trials.
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Surgical resection is the mainstay of treatment of GIST. Tu-
mor size, mitotic index, gastric origin and primary presenta-
tion are important predictors for disease speciﬁc survival in
patients presenting with primary disease. It is still too early
to come up with universal methods for the therapy of GIST
patients. Considerable research efforts are required to explore
the current thinking in the management of GIST, with partic-
ular emphasis on the impact of recent data regarding the man-
agement of GIST in the adjuvant setting. The door is open
wide on future studies until we settle on solid guidelines for
the management of GIST.References
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